Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab long-term open-label extension in coronary artery disease
NL-OMON41952Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of evolocumab in hypercholesterolemia and coronary arteriosclerosis, sponsored by Amgen. Primary endpoint: Subject incidence of adverse events. Started Apr 2015; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiacoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON41952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41952.